sur VALNEVA (EPA:VLA)
Valneva General Meeting Approves Key Resolutions
On June 25, 2025, Valneva SE, a specialty vaccine company, announced the successful outcome of its Annual General Meeting in Lyon, France. Shareholders approved all resolutions proposed by the Board of Directors.
Significant resolutions included the approval of the 2024 financial statements, authorizations to increase the company's share capital, and the issuance of new financial instruments. Moreover, Dr. Gerd Zettlmeissl, a vaccine expert, was appointed to the Board for a three-year term, while Mr. James Sulat was reappointed for another year. Deloitte & Associés’ term as Statutory Auditor was extended for six years.
The company's management confirmed Valneva's financial guidance for the fiscal year 2025. Detailed voting results will be available on Valneva's website.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALNEVA